VidaNomi is a health tech startup focused on providing cutting-edge solutions for early detection and prevention in gut healthcare. By combining AI, smart pill technology and seamless integration with existing health systems, VidaNomi is set to transform the way digestive issues are diagnosed and treated worldwide. The company is committed to improving patient outcomes and reducing healthcare costs through innovative, non-invasive technologies.

PRESS RELEASES:
Tampere, FINLAND Dec 8th, 2024: VidaNomi Announces Seed Round for Revolutionary AI-Powered Health Technology
VidaNomi, an innovative health tech company dedicated to transforming digestive healthcare, is thrilled to announce the launch of its seed funding round. The company is set to revolutionize early diagnosis and predictive healthcare through cutting-edge AI and a groundbreaking smart pill equipped with wireless power capabilities and real-time data, offering a non-invasive and accessible solution for patients worldwide.
VidaNomi’s flagship product is a multi-sensor smart pill designed to provide real-time data on digestive health. Paired with the company's AI-powered health analysis platform, this solution promises faster, more accurate diagnostics, reduced hospital visits and empowered patients through proactive, personalized care. The platform will leverage existing health data to offer predictive insights, enabling healthcare providers to detect and manage gastrointestinal diseases, like colorectal cancer, before they become critical.
“Our mission is to make early diagnosis and prevention accessible to everyone,” said Fahad Sohrab, CTO of VidaNomi. “With a strong, experienced team and proven technology, we are positioning ourselves at the intersection of AI, healthcare and sustainability. This seed round will allow us to further develop our platform and smart pill, bringing us closer to our goal of improving global health outcomes.”
VidaNomi plans to initially target public hospitals and private healthcare practices across Finland, with plans to expand into the rest of Europe, then to the USA, the Middle East and Asia. The company’s subscription-based model offers a free base version of its platform to build a strong user base, with premium features and device sales providing significant revenue streams.
The funds raised will be allocated towards platform development, securing IP protection for the smart pill and scaling the business to meet the growing demand for predictive healthcare solutions and prepare the device for medical animal and human trials. 
VidaNomi is aiming to raise €3.5 million in this seed round.
With the AI diagnostics, predictive healthcare and other relative markets projected to reach over €1.6 trillion by 2030, VidaNomi is poised to capitalize on this rapidly growing sector, offering sustainable, scalable solutions for healthcare providers, patients and investors alike.
For media inquiries or more information about the seed round, please contact:
Fahad Sohrab, CTO
VidaNomi
vidanomi@iine.studio
vidanomi.com
Logos for press use (right click to save):
↑Back to Top